Janssen Owes Family $10M In Topamax Suit, Jury Says

By Kurt Orzeck (November 18, 2013, 9:45 PM EST) -- A Philadelphia state jury decided on Monday that Janssen Pharmaceuticals Inc. is obligated to pay more than $10 million to the parents of a child who allegedly suffered birth defects due to the company's epilepsy drug Topamax, according to attorneys for the family.

The jury determined that the Johnson & Johnson unit didn't sufficiently warn doctors about the risk of birth defects stemming from the use of the drug, plaintiffs' counsel said. The company allegedly knew about the risks years before the drug was prescribed to patients, according to the lawyers.

The family's 5-year-old child allegedly developed a cleft palate and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!